A Comparison of Inpatient and Outpatient ASCT
Overview
Authors
Affiliations
Outpatient high-dose chemotherapy and autologous stem cell transplantation (ASCT) has been shown to be feasible in terms of physical morbidity and mortality outcomes, but few data exist on the psychosocial impact of delivering such aggressive therapy in this manner. The purpose of this observational study was to compare effects of inpatient (n = 20) and outpatient (n = 21) modes of care on physical status, psychological well-being, quality of life, personal finances and caregiver burden. Most patients were treated according to their preference for inpatient or outpatient care. Those choosing outpatient care were screened for eligibility according to established criteria for ambulatory management. Measures were taken at baseline, then at days 4-6, 12-16 and 30 post ASCT. Results showed that overall, the psychological, physical, social and financial outcomes of the outpatient ASCT group were comparable, to or better than inpatients. Factors that seem to be important for successful outpatient management are previous experience with cancer treatment, a satisfying quality of life, physical well-being, patient's preference for a particular mode of care and physical proximity to the treatment centre. The study results suggest that outpatient ASCT is an efficient, effective and acceptable form of care for motivated patients and caregivers who have the physical and psychological capability and desire to receive cancer treatment in this manner.
Prieto Del Prado M, Fernandez Aviles F Front Immunol. 2024; 15:1419186.
PMID: 39081323 PMC: 11287121. DOI: 10.3389/fimmu.2024.1419186.
Hansen D, Dhakal B, Hamadani M, Dingli D, Jain T, Huff C Front Immunol. 2024; 15:1405452.
PMID: 38915401 PMC: 11194690. DOI: 10.3389/fimmu.2024.1405452.
Chimeric antigen receptor T-cell therapy: Challenges and framework of outpatient administration.
Gatwood K, Dholaria B, Lucena M, Baer B, Savani B, Oluwole O EJHaem. 2022; 3(Suppl 1):54-60.
PMID: 35844300 PMC: 9176074. DOI: 10.1002/jha2.333.
Gonzalez M, Urizar E, Urtaran-Laresgoiti M, Nuno-Solinis R, Lazaro-Perez E, Vazquez L PLoS One. 2021; 16(8):e0254135.
PMID: 34383780 PMC: 8360565. DOI: 10.1371/journal.pone.0254135.
Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.
Martino M, Paviglianiti A, Memoli M, Martinelli G, Cerchione C Front Oncol. 2020; 10:592487.
PMID: 33262948 PMC: 7686536. DOI: 10.3389/fonc.2020.592487.